Purpose Of Review: The prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients.
Recent Findings: As we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway.
Summary: Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986373 | PMC |
http://dx.doi.org/10.1097/ICU.0000000000000569 | DOI Listing |
Int Ophthalmol
January 2025
Second Department of Ophthalmology, The First People's Hospital of Aksu, Aksu, 843000, Xinjiang Autonomous Region, China.
Purpose: We aimed to evaluate the effects of autologous serum plus artificial tears on corneal sensation and tear film stability in patients with mild to moderate xerophthalmia after cataract surgery.
Methods: A total of 150 patients with mild to moderate xerophthalmia after one-time cataract surgery from March 2022 to September 2023 were selected and randomly divided into a control group (n = 75) and a study group (n = 75). The control group was treated with artificial tears (polyvinyl alcohol eye drops), while the study group was given autologous serum plus artificial tears.
J Cataract Refract Surg
January 2025
University Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.
Purpose: To evaluate the symptoms, etiology and treatment of patient dissatisfaction after extended depth-of-focus (EDOF) intraocular lens (IOL) implantation.
Setting: University Eye Clinic, Maastricht University Medical Center, the Netherlands.
Design: Retrospective case series.
Bioengineering (Basel)
January 2025
Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore 169856, Singapore.
Terahertz (THz) waves reside in the electromagnetic spectrum between the microwave and infrared bands. In recent decades, THz technology has demonstrated its potential for biomedical applications. With the highly unique characteristics of THz waves, such as the high sensitivity to water and optimal spatial resolution coupled with the characteristics of the human cornea, such as its high water content, THz technology has been explored as a potential modality to assess corneas and corneal diseases.
View Article and Find Full Text PDFBMJ Surg Interv Health Technol
January 2025
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University; Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing, People's Republic of China.
Objectives: To address the lack of nerve and blood supply after labial salivary gland transplantation (LSGT) resulting in glandular atrophy. We designed a modified LSGT, called insular infraorbital neurovascular pedicle LSGT, and evaluated the postoperative efficacy.
Design: This is a prospective, single-centre, self-contained study.
J Ophthalmol
January 2025
Department of Ophthalmology, Oslo University Hospital, P.O. Box 4950, Nydalen, Oslo 0424, Norway.
Dry eye disease (DED) is a multifactorial disorder affecting millions worldwide. Inflammation plays a central role in DED. The aim of this review is to critically evaluate the literature concerning the efficacy and safety of lifitegrast, a small molecule immunomodulator that blocks the action of lymphocyte function-associated antigen-1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!